4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Annovis Bio, Inc. (ANVS) operates in the Biotechnology industry and is headquartered in Malvern, United States with about 7 employees. Its market capitalization is roughly $71 million. In the fiscal year ended 2025-12-31, ANVS reported $0M in revenue and ($29M) in net income.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($30M) | ($27M) | ($45M) | ($26M) | — |
| Net Income | ($29M) | ($25M) | ($56M) | ($25M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($18M) | ($10M) | ($7M) | ($6M) | ($6M) | — |
| Net Income | ($18M) | ($10M) | ($7M) | ($6M) | ($6M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $21M | $14M | $10M | $36M |
| Total Liabilities | $4M | $5M | $18M | $8M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ANVS viewer.
About TickerBase · Data methodology & sources